Supporting evidence
Semaglutide × Body weight
- Authoritative support
- 9
- Available studies
- 9
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Generic semaglutide is as effective as innovator version for diabetes control
Rct
- Comparison
- Participants received generic semaglutide for 24 weeks in a step wise dose escalation. · Participants received innovator semaglutide for 24 weeks in a step wise dose escalation.
- Duration / follow-up
- 24 weeks
Study 2 · Included
Higher semaglutide doses improve glucose control in type 2 diabetes
Rct
- Comparison
- Participants received 2 mg of semaglutide weekly for 40 weeks. · Participants received 8 mg of semaglutide weekly for 40 weeks. · Participants received 16 mg of semaglutide weekly for 40 weeks. · Participants received a matching placebo for 40 weeks.
- Duration / follow-up
- 9 weeks
Relevant effect
Mean difference
3.4 · 0.011
Study 3 · Included
Novel Semaglutide Injection Shows Non-Inferior Glycemic Control
Rct
- Comparison
- Patients received once weekly semaglutide injection for 24 weeks. · Patients received reference semaglutide injection for 24 weeks.
- Duration / follow-up
- 24 weeks
Relevant effects
Absolute change
4.59
Absolute change
1.76
Study 4 · Included
Once-weekly semaglutide improves glycemic control in Korean adults with T2D
Rct
- Comparison
- Participants received OW s.c. semaglutide 0.5 mg. · Participants received OW s.c. semaglutide 1.0 mg. · Participants received OD oral sitagliptin 100 mg.
- Duration / follow-up
- 30 weeks
Relevant effects
Absolute change
2.7
Percent change
42.9
Absolute change
4.8
Percent change
65
Absolute change
0.5
Percent change
0
Study 5 · Included
Oral semaglutide improves glycemic control in type 2 diabetes
Rct
- Comparison
- Participants received once daily oral semaglutide 3 mg. · Participants received once daily oral semaglutide 7 mg. · Participants received once daily oral semaglutide 14 mg. · Participants received once daily oral sitagliptin 100 mg.
- Duration / follow-up
- 26 weeks
Relevant effects
Mean difference
0.9 · 0.001
Mean difference
2.3 · 0.001
Mean difference
3.3 · 0.001
Mean difference
3.3 · 0.001
Study 6 · Included
Semaglutide improves glycemic control more than insulin aspart in type 2 diabetes
Rct
- Comparison
- Participants received once weekly semaglutide as add on to optimized insulin glargine and metformin. · Participants received thrice daily insulin aspart as add on to optimized insulin glargine and metformin.
- Duration / follow-up
- 52 weeks
Relevant effects
Absolute change
4.1
Absolute change
2.8
Study 7 · Included
Semaglutide reduces cardiovascular events and body weight in T2D
Rct
- Comparison
- Participants received semaglutide to evaluate cardiovascular, metabolic, and safety outcomes. · Participants received a dose matched placebo as a comparator to semaglutide.
- Duration / follow-up
- 3380 weeks
Relevant effect
Mean difference
3 · 0.124
Study 8 · Included
Survodutide improves HbA1c and bodyweight in type 2 diabetes
Rct
- Comparison
- Participants received 0.3 mg of survodutide once weekly. · Participants received 0.9 mg of survodutide once weekly. · Participants received 1.8 mg of survodutide once weekly. · Participants received 2.7 mg of survodutide once weekly. · Participants received 1.2 mg of survodutide twice weekly. · Participants received 1.8 mg of survodutide twice weekly. · Participants received 1.0 mg of semaglutide once weekly. · Participants received a placebo.
- Duration / follow-up
- 16 weeks
Relevant effect
Percent change
8.7
Study 9 · Included
Tirzepatide shows greater HbA1c and weight reduction than Semaglutide
Rct
- Comparison
- Participants received 5 mg of Tirzepatide. · Participants received 10 mg of Tirzepatide. · Participants received 15 mg of Tirzepatide. · Participants received 1 mg of Semaglutide.
- Duration / follow-up
- 40 weeks
Relevant effects
Absolute change
6.9 · 0.001
Absolute change
9.7 · 0.001
Absolute change
10.5 · 0.001
Absolute change
5.6 · 0.001